Antibody Profiling in COVID-19 Patients with Different Severities by Using Spike Variant Protein Microarrays

Wen Yu Su, Pin Xian Du, Harvey M. Santos, Tzong Shiann Ho, Batuhan Birol Keskin, Chi Ho Pau, An Ming Yang, Yi Yu Chou, Hsi Chang Shih, Guan Da Syu

Research output: Contribution to journalArticlepeer-review


The disease progression of COVID-19 varies from mild to severe, even death. However, the link between COVID-19 severities and humoral immune specificities is not clear. Here, we developed a multiplexed spike variant protein microarray (SVPM) and utilized it for quantifying neutralizing activity, drug screening, and profiling humoral immunity. First, we demonstrated the competition between antispike antibody and ACE2 on SVPM for measuring the neutralizing activity against multiple spike variants. Next, we collected the serums from healthy subjects and COVID-19 patients with different severities and profile the neutralizing activity as well as antibody isotypes. We identified the inhibition of ACE2 binding was stronger against multiple variants in severe compared to mild/moderate or critical patients. Moreover, the serum IgG against nonstructural protein 3 was elevated in severe but not in mild/moderate and critical cases. Finally, we evaluated two ACE2 inhibitors, Ramipril and Perindopril, and found the dose-dependent inhibition of ACE2 binding to all the spike variants except for B.1.617.3. Together, the SVPM and the assay procedures provide a tool for profiling neutralizing antibodies, antibody isotypes, and reagent specificities.

Original languageEnglish
Pages (from-to)6529-6539
Number of pages11
JournalAnalytical Chemistry
Issue number17
Publication statusPublished - 2022 May 3

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry


Dive into the research topics of 'Antibody Profiling in COVID-19 Patients with Different Severities by Using Spike Variant Protein Microarrays'. Together they form a unique fingerprint.

Cite this